In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

The insulins available without a prescription come in vials and pens that may need ... you’re looking to use OTC insulin, you may also want to consider Eli Lilly’s affordable options, which ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

New Delhi, Jan 9 (PTI) Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Thus, it is no surprise that he was recognized earlier in the day for his sportsmanship … Aubrey wins Bob Lilly Award: Aubrey’s wife, Jenn, was on the field during pregame for the Bob Lilly ...

Diabetes mellitus is a metabolic disease that causes high blood sugar. Your body either doesn’t make enough insulin or can’t effectively use the insulin it makes. The hormone insulin moves ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.